mercredi 6 novembre 2019

Onco Actu du 6 novembre 2019


1. BIOLOGIE



Some Skin Cancers May Start in Hair Follicles [NYU Langone Health]











3.1.1 PRÉVENTION - TABAC - E-CIGS



NIH-funded study finds teens prefer mint and mango vaping flavors [NIH]










E-cigarette vapor linked to cancer in mice [NIH]











e-Cigarette Use Among Youth in the United States, 2019 [JAMA]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



The advent and rise of monoclonal antibodies [Nature]










5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform [Takeda]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



To Monitor Cancer Therapy in the Body, Penn Researchers Tag CAR T Cells with Imaging Markers [Penn Medicine]











5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Pembrolizumab as a Combination or Monotherapy in First-line Treatment for Recurrent or Metastatic HNSCC [ESMO]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Regeneron defends bid to challenge Merck in lung cancer [Biopharma Dive]











5.2.1 PHARMA - PARTENARIATS



On the heels of a $6.9B AstraZeneca pact, IP dispute between Daiichi Sankyo and Seattle Genetics rips open in lawsuit [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



AstraZeneca announces three large-scale initiatives in China to advance global medicine research and development [AstraZeneca]











Britain's AstraZeneca launches $1 billion China investment fund with CICC [Reuters]











5.2.6 PHARMA - BIOTECH



The next biotech superpower [Nature Biotechnology]










5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



After years-long delay, Novartis' Sandoz finally wins Neulasta biosimilar nod [Fierce Pharma]











Third Neulasta biosimilar on its way as Sandoz wins long-delayed FDA approval [Biopharma Dive]











Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez) [Novartis]











It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster [EndPoints]











6.1 OBSERVATION



Diabetes may distract women from cancer screenings [Reuters]










6.6 PUBLICATIONS



Trainees Often Ghostwrite PIs’ Peer Reviews: Survey [The Scientist]











6.7.1 IA/BIOINFORMATIQUE



Make code accessible with these cloud services [Nature]